Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
07.05. | What Analysts Are Saying About TScan Therapeutics Stock | 4 | Benzinga.com | ||
07.05. | H.C. Wainwright cuts Tscan stock target to $10, keeps Buy rating | 2 | Investing.com | ||
06.05. | TScan Therapeutics GAAP EPS of $0.26 | 5 | Seeking Alpha | ||
06.05. | TScan Therapeutics May 2025 slides: advancing TCR-T therapies with positive Phase 1 data | 1 | Investing.com | ||
06.05. | TScan Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
TSCAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
28.04. | TScan Therapeutics, Inc.: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting | 1 | GlobeNewswire (USA) | ||
08.04. | Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts | 1 | Benzinga.com | ||
27.03. | TScan Therapeutics, Inc.: TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access | 2 | GlobeNewswire (USA) | ||
06.03. | Breaking Down TScan Therapeutics: 4 Analysts Share Their Views | 1 | Benzinga.com | ||
05.03. | TScan Therapeutics files for $300M mixed securities shelf | 2 | Seeking Alpha | ||
05.03. | TScan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
05.03. | TScan Therapeutics GAAP EPS of $0.30, revenue of $0.67M | 1 | Seeking Alpha | ||
05.03. | TScan Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | TScan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
26.12.24 | Why Is TScan Therapeutics Stock Gaining Today? | 3 | Benzinga.com | ||
26.12.24 | TScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% Premium | 1 | RTTNews | ||
26.12.24 | TScan Therapeutics announces ~$30M direct offering | 1 | Seeking Alpha | ||
26.12.24 | TScan sichert sich 30 Millionen US-Dollar durch Optionsscheinverkauf an Lynx1 | 4 | Investing.com Deutsch | ||
26.12.24 | TScan secures $30 million through warrant sale to Lynx1 | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
MEDIGENE | 0,133 | -4,68 % | Medigene AG: Widerruf der Zulassung (Prime Standard) | Beschluss
Medigene AG, Planegg/Martinsried
Widerruf der Zulassung zum Teilbereich des regulierten Marktes mit weiteren Zulassungsfolgepflichten (Prime Standard) von Amts wegen
Die Zulassung... ► Artikel lesen | |
AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
BIOFRONTERA | 2,500 | 0,00 % | Biofrontera sichert Patent für Ameluz-Formulierung bis 2043 | ||
BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
REGENERON PHARMACEUTICALS | 434,60 | +0,44 % | Regeneron-Aktie crasht nach COPD-Daten - Verona Pharma schießt auf Allzeithoch | Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum COPD-Hoffnungsträger Itepekimab... ► Artikel lesen | |
EDITAS MEDICINE | 1,681 | 0,00 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
GALAPAGOS NV | 24,420 | +0,25 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new... ► Artikel lesen | |
IMMATICS | 5,300 | +1,34 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
AYALA PHARMACEUTICALS | 0,010 | 0,00 % | OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline | NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced... ► Artikel lesen | |
AUTOLUS THERAPEUTICS | 2,060 | 0,00 % | Autolus bei Jefferies-Konferenz: Strategisches Wachstum im Gesundheitssektor | ||
IGM BIOSCIENCES | 0,945 | -14,09 % | IGM Biosciences, Inc.: IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs | - Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) - - Company reducing its workforce by 73% - - Cash and investments of $183.8 million (unaudited) as of December... ► Artikel lesen | |
ONCOPEPTIDES | 0,135 | -0,44 % | Oncopeptides AB: Bulletin from the Annual General Meeting in Oncopeptides AB (publ) | Stockholm, Sweden - The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 22 May 2025. At the Annual General Meeting, the following principal resolutions were passed.
The... ► Artikel lesen | |
AVACTA | 0,396 | -2,94 % | Avacta Group reports FY results |